



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Road,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### New BioDiem Board Appointment

**Melbourne, 25 February 2022:** Australian vaccine technology company BioDiem Ltd (“BioDiem”) is pleased to announce the appointment of Mr Damien Hannes as a non-executive director, effective 24 February 2022.

Mr. Hannes has over 25 years of finance, operations, sales and management experience. He has most recently served over 15 years as a managing director and a member of the operating committee, among other senior management positions, for Credit Suisse’s listed derivatives business in equities, commodities and fixed income in its Asia and Pacific region. From 1986 to 1993, Mr. Hannes was a director for Fay Richwhite Australia, a New Zealand merchant bank. Prior to his tenure with Fay Richwhite, Mr. Hannes was the director of operations and chief financial officer of Donaldson, Lufkin and Jenrette Futures Ltd, a US investment bank. He has successfully raised capital and developed and managed mining, commodities trading and manufacturing businesses in the global market. He holds a Bachelor of Business degree from the NSW University of Technology and subsequently completed the Institute of Chartered Accounts Professional Year before being seconded into the commercial sector.

From 2009 to 2019 Mr Hannes was a non-executive director of Sundance Energy Australia Ltd (ASX) and Sundance Energy Inc (NASDAQ) after a re-domicile to the US. Damien was Chairman of the remuneration committee and a member of the audit committee in his time on the board at Sundance Energy. Damien has held various other Directorships in other private businesses in a capacity as Chairman and as a non executive Director.

Mr Hugh Morgan AC, chairman of the BioDiem board said “The directors warmly welcome Damien and the contribution his diverse experience will bring to the board.”

- ENDS -

## About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem’s business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem’s lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

Biodiem has two commercial licences:

- Changchun BCHT Biotechnology Co (China) launched Defluvac™ in China in August 2020; and
- Serum Institute of India’s Nasovac-S™ is marketed in India.

**Further information**

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

Twitter @biodiem @opalbiosciences